Clinical efficacy study of sunitinib combined with capecitabine in the treatment of triple-negative breast cancer
Objective To investigate the clinical efficacy of sunitinib combined with capecitabine in the treatment of tri-ple-negative breast cancer(TNBC).Methods TNBC patients treated at Hebei Petro China Central Hospital from March 2020 to March 2022 were selected for this study.Patients were divided into the control group and the study group using the a ran-dom number table method.The control group received capecitabine treatment,while the study group received additional suni-tinib treatment,with both groups undergoing three treatment cycles.The therapeutic effects,immune function,serum CA153,TPS,TK1 levels,patient quality of life,and adverse reactions were evaluated for both groups.Results A total of 60 patients were included,with 30 cases in the control group and 30 cases in the study group.After three treatment cycles,no significant difference in the objective response rate was observed between the two groups(P>0.05).However,the disease control rate in the study group was higher than that of the control group(86.67%vs 60.00%).The levels of CD3+,CD4+,CD4+/CD8+,FACT-B,and SAQ scores were higher than those of the control group[(49.26±3.11)vs(41.02±3.46),(42.55±5.11)vs(35.16±4.18),(1.98±0.22)vs(1.66±0.36),(85.12±1.65)points vs(72.65±1.48)points,(143.65±2.78)points vs(135.26±3.16)points],CD8+,serum CA153,TPS,TK1 levels,and HADS scores were lower than those of the control group[(16.56±1.87)vs(21.34±2.15),(20.45±3.79)U/mL vs(24.22±4.12)U/mL,(5.45±1.46)ng/mL vs(7.11±2.01)ng/mL,(1.56±0.26)pmol/L vs(1.91±0.23)pmol/L,(10.33±1.08)points vs(12.22±1.02)points],the differences were statisti-cally significant(P<0.05).Follow-up showed that the study group had longer disease control time[8.85(6.11,9.26)months]and progression-free survival[5.16(4.87,6.78)months]than those of the control group[7.11(5.26,8.78)months and 4.89(3.98,5.65)months](P<0.05).The incidence rates of adverse reactions such as fever,anemia,nausea and vomiting were similar between the two groups(P>0.05).Conclusion Sunitinib combined with capecitabine treatment for TNBC shows promising efficacy,significantly improving disease control rates,enhancing immune function and quality of life,reducing serum CA153,TPS,TK1 levels,and maintaining high safety.
sunitinibcapecitabinetriple-negative breast cancerimmune functionclinical efficacy
NETL
NSTL
万方数据
